Health Affairs, 23, no. 1 (2004): 77-87 doi: 10.1377/hlthaff.23.1.77 © 2004 by Project HOPE	New Online   Pay Cuts For Medicare Docs   Access To Care Woes   Public Coverage More Efficient   Empowering Consumers

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Califf, R. M. Search for Related Content PubMed PubMed Citation Articles by Califf, R. M. Related Collections Pharmaceuticals Research And Technology

Environment

Defining The Balance Of Risk And Benefit In The Era Of Genomics And Proteomics

The ability to measure the function of genes and proteins has spawned the construct of personalized medicine, in which patients’ own risks and preferences are used to choose diagnostic and therapeutic strategies. The complexity of clinical data required to guide personalized medicine calls for improvements in our system of clinical research, including (1) overhauling it to produce networks that can do adequate-size pragmatic trials; (2) synchronization of regulatory and payment systems to encourage adequate studies; and (3) an investment in education of providers and patients to improve the understanding of the probabilistic predictions forming the basis of personalized medicine.

                      What's this?

This article has been cited by other articles:

				R. M. Califf, R. A. Harrington, L. K. Madre, E. D. Peterson, D. Roth, and K. A. Schulman Curbing The Cardiovascular Disease Epidemic: Aligning Industry, Government, Payers, And Academics Health Aff., January 1, 2007; 26(1): 62 - 74. [Abstract] [Full Text] [PDF]

				L. P. Garrison Jr. and M.J. F. Austin Linking Pharmacogenetics-Based Diagnostics And Drugs For Personalized Medicine Health Aff., September 1, 2006; 25(5): 1281 - 1290. [Abstract] [Full Text] [PDF]

				R. M. Califf Simple Principles of Clinical Trials Remain Powerful JAMA, January 26, 2005; 293(4): 489 - 491. [Full Text] [PDF]

				R. M. Califf, T. Ryan, P. Douglas, and P. J. Goldschmidt-Clermont A time of accelerated change in academic cardiovascular medicine: Implications for academic divisions of cardiology and their training programs J. Am. Coll. Cardiol., November 16, 2004; 44(10): 1957 - 1965. [Abstract] [Full Text] [PDF]

				R. Snyderman The Clinical Researcher--An "Emerging" Species JAMA, February 18, 2004; 291(7): 882 - 883. [Full Text] [PDF]